Compositions and methods for modulating bone mineral deposition
View Patent ↗The key function of TNAP in bone is degradation of PPi to remove this mineralization inhibitor and provide free phosphate for apatite deposition. PC-1 is a direct antagonist of TNAP function. ANK also antagonizes TNAP-dependent matrix calcification. Specifically, the activity of PC-1 inhibits initial MV apatite deposition, but ANK inhibits propagation of apatite outside the MVs. Furthermore, loss of function of the two distinct skeletal TNAP antagonists, PC-1 and ANK, ameliorates TNAP deficiency-associated osteomalacia in vivo. Conversely, the hyperossification associated with both PC-1 null mice and ANK-deficient (ank/ank) mice is ameliorated by deficiency of TNAP in vivo.
1. A method for decreasing matrix mineralization in a tissue of a patient having a disease associated with insufficient or deficient ankylosis protein (ANK) activity or expression compared to normal ANK activity or expression, comprising administering an amount of a tissue non-specific alkaline phosphatase (TNAP) inhibitor selected from the group consisting of L-tetramisole, D-tetramisole, levamisole, dexamisole, L-homoarginine, teophyllin and forphenicine to the tissue or patient effective to inhibit TNAP expression or activity.
2. The method of claim 1 wherein said tissue comprises bone, cartilage or ligament.
3. The method of claim 1 wherein said tissue exhibits undesirable or excessive matrix mineralization.
4. The method of claim 1 wherein said patient is affected by the disease selected from the group consisting of arterial calcification, ankylosing spondylitis, ossification of the posterior longitudinal ligament, myositis ossificans, diffuse idiopathic skeletal hyperostosis, calcific tendonitis, rotator cuff disease of the shoulders, osteomalacia, metabolic bone disease associated with renal failure, bone spurs, cartilage or ligament degeneration due to hydroxyapatite crystal deposition, chondrocalcinosis and osteoporosis.
5. The method of claim 4 , wherein one or more symptoms of said disease is reduced.
6. A method of treating a patient having a disease selected from the group consisting of arterial calcification, ankylosing spondylitis, ossification of the posterior longitudinal ligament, myositis ossificans, diffuse idiopathic skeletal hyperostosis, calcific tendonitis, rotator cuff disease of the shoulders, osteomalacia, metabolic bone disease associated with renal failure, bone spurs, cartilage or ligament degeneration due to hydroxyapatite crystal deposition, chondrocalcinosis and osteoporosis, caused at least in part by deficient ANK activity or expression, comprising administering a compound selected from the group consisting of L-tetramisole, D-tetramisole, levamisole, dexamisole, L-homoarginine, teophyllin and forphenicine, wherein the compound reduces expression or activity of TNAP in a tissue of the patient affected by the disease.
7. The method of claim 6 , comprising administering to said patient an amount of a TNAP inhibitor effective to reduce one or more symptoms of said disease.